Manageable Safety Profile and Antitumour Activity of Zongertinib in Pretreated Patients with HER2-altered Tumours, Including NSCLC By Ogkologos - March 17, 2025 307 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the Beamion LUNG-1 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma Mortality Trends for Most Cancers Remain Favourable In the EU, Although the Absolute Number of Cancer Deaths Is Not Declining Due To Population Ageing MOST POPULAR Cómo mi diagnóstico de cáncer a los 17 años cambió mi... December 14, 2020 Whipple Procedure for Pancreatic Cancer: How to Prepare and What to... September 16, 2021 Survivors of Childhood Cancer are at Excess Risk of Late Mortality... April 21, 2023 EMA Recommends Granting a Conditional Marketing Authorisation for Zanidatamab June 5, 2025 Load more HOT NEWS Study presents an AI-guided approach to target cancer antigens Should Surgery And Radiation Be The Standard Treatment For DCIS? The... Treating the Whole Person: How Cancer Centers Are Addressing Social Needs Melanoma Combination Studies with a Novel Anti-LAG3 Antibody Relatlimab
